Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/oxford-university-press/breakthrough-fungal-infections-in-stem-cell-transplant-recipients-SIv8ap7zix
References (25)
-
S. Aşçıoğlu, J. Rex, B. Pauw, J. Bennett, J. Billé, F. Crokaert, D. Denning, J. Donnelly, J. Edwards, Z. Erjavec, D. Fiére, O. Lortholary, J. Maertens, J. Meis, T. Patterson, J. Ritter, D. Selleslag, P. Shah, D. Stevens, T. Walsh (2002)
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 34 1
-
P. Verweij, M. Bergh, P. Rath, B. Pauw, A. Voss, J. Meis (1999)
Invasive Aspergillosis Caused by Aspergillus ustus: Case Report and ReviewJournal of Clinical Microbiology, 37
-
R. Ally, D. Schürmann, W. Kreisel, G. Carosi, K. Aguirrebengoa, B. Dupont, M. Hodges, P. Troke, A. Romero (2001)
A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 33 9
-
(2002)
Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved standard M38-A -
E. Dannaoui, J. Meletiadis, J. Mouton, J. Meis, P. Verweij (2003)
In vitro susceptibilities of zygomycetes to conventional and new antifungals.The Journal of antimicrobial chemotherapy, 51 1
-
A. Espinel-Ingroff (2001)
In Vitro Fungicidal Activities of Voriconazole, Itraconazole, and Amphotericin B against Opportunistic Moniliaceous and Dematiaceous FungiJournal of Clinical Microbiology, 39
-
F. Marty, L. Cosimi, L. Baden (2004)
Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.The New England journal of medicine, 350 9
-
D. Denning, P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, H. Lode (2002)
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 34 5
-
M. Pfaller, D. Diekema, S. Messer, L. Boyken, R. Hollis (2003)
Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001Journal of Clinical Microbiology, 41
-
L. Ostrosky-Zeichner, J. Rex, P. Pappas, R. Hamill, R. Larsen, H. Horowitz, W. Powderly, N. Hyslop, C. Kauffman, J. Cleary, J. Mangino, Jeannette Lee (2003)
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United StatesAntimicrobial Agents and Chemotherapy, 47
-
M. Pfaller, Ronald Jones, G. Doern, H. Sader, S. Messer, A. Houston, S. Coffman, R. Hollis (2000)
Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998Antimicrobial Agents and Chemotherapy, 44
-
K. Sullivan, E. Agura, C. Anasetti, F. Appelbaum, C. Badger, S. Bearman, K. Erickson, M. Flowers, J. Hansen, T. Loughran (1991)
Chronic graft-versus-host disease and other late complications of bone marrow transplantation.Seminars in hematology, 28 3
-
M. Mcginnis, L. Pasarell, D. Sutton, A. Fothergill, C. Cooper, M. Rinaldi (1997)
In vitro evaluation of voriconazole against some clinically important fungiAntimicrobial Agents and Chemotherapy, 41
-
R. Herbrecht, D. Denning, T. Patterson, J. Bennett, R. Greene, J. Oestmann, W. Kern, K. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. Rubin, J. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. Chandrasekar, M. Hodges, H. Schlamm, P. Troke, B. Pauw (2002)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.The New England journal of medicine, 347 6
-
M. Nguyen, J. Peacock, A. Morris, D. Tanner, Minh-Ly Nguyen, D. Snydman, M. Wagener, M. Rinaldi, V. Yu (1996)
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.The American journal of medicine, 100 6
-
D. Przepiorka, D. Weisdorf, P. Martin, H. Klingemann, P. Beatty, J. Hows, E. Thomas (1995)
1994 Consensus Conference on Acute GVHD Grading.Bone marrow transplantation, 15 6
-
T. Walsh, I. Lutsar, T. Driscoll, B. Dupont, M. Roden, P. Ghahramani, M. Hodges, A. Groll, J. Perfect (2002)
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in childrenThe Pediatric Infectious Disease Journal, 21
-
J. Meletiadis, J. Meis, J. Mouton, Juan Rodriquez-Tudela, J. Donnelly, P. Verweij, the Network (2002)
In Vitro Activities of New and Conventional Antifungal Agents against Clinical Scedosporium IsolatesAntimicrobial Agents and Chemotherapy, 46
-
Qiu Sun, A. Fothergill, D. McCarthy, M. Rinaldi, J. Graybill (2002)
In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of ZygomycetesAntimicrobial Agents and Chemotherapy, 46
-
K. Marr, R. Carter, F. Crippa, A. Wald, L. Corey (2002)
Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 34 7
-
J. Greig, A. Brown (2004)
Bloodstream infections due to Candida species.The Journal of hospital infection, 56 3
-
A. Groll, T. Walsh (2002)
Antifungal chemotherapy: advances and perspectives.Swiss medical weekly, 132 23-24
-
L. Ostrosky-Zeichner, A. Lashof, B. Kullberg, J. Rex, J. Rex (2003)
Voriconazole Salvage Treatment of Invasive CandidiasisEuropean Journal of Clinical Microbiology and Infectious Diseases, 22
-
R. Kappe (1999)
Antifungal activity of the new azole UK‐109, 496 (voriconazole)Mycoses, 42
-
J. Perfect, K. Marr, T. Walsh, R. Greenberg, B. Dupont, J. Torre-Cisneros, G. Just-Nübling, H. Schlamm, I. Lutsar, A. Espinel-Ingroff, Elizabeth Johnson (2003)
Voriconazole treatment for less-common, emerging, or refractory fungal infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 36 9
- Publisher
- Oxford University Press
- Copyright
- © Published by Oxford University Press.
- Subject
- Brief Reports
- ISSN
- 1058-4838
- eISSN
- 1537-6591
- DOI
- 10.1086/423274
- pmid
- 15356792
- Publisher site
- See Article on Publisher Site
Abstract
Infection with voriconazole-resistant fungi may become problematic, because organisms with decreased susceptibility have been noted. Breakthrough fungal infections occurred in 13 of 139 patients who received voriconazole at our center during the period of September 1998 through September 2003. Zygomycetes were found in 6 patients, and Candida glabrata bloodstream infection occurred in 4 patients. Minimal inhibitory concentrations were ⩾1 µg/mL for all available isolates. Yeasts and molds with decreased susceptibility to voriconazole may cause invasive infection in patients treated successfully for aspergillosis.
Journal
Clinical Infectious Diseases – Oxford University Press
Published: Sep 1, 2004